Febrile morbidity · women with non‐labour caesarean section
Cervical dilatation showed no clear difference in febrile morbidity (at least 38° Celsius, measured on 2/10 days… compared with no dilatation (low certainty).
1 finding from 1 review
Participants infectious at day 8 · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg may leads to lower participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).
2 findings from 1 review
Participants infectious at day 8 · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.75 mg/kg showed no clear difference in participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).
2 findings from 1 review
Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.75 mg/kg showed no clear difference in participants with gametocytes at day 3‐4, by PCR compared with no primaquine, with artemisinin partner, (low certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.75 mg/kg leads to lower participants with gametocytes at day 8, by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
Participants with gametocytes at day 4‐5, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with gametocytes at day 4‐5, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.4 to 0.5 mg/kg probably leads to lower participants with gametocytes at day 8, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.75 mg/kg probably leads to lower participants with gametocytes at day 8, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg showed no clear difference in participants with gametocytes at day 3 to 4 by PCR compared with no primaquine, with artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg leads to lower participants with gametocytes at day 8 by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
Participants infectious at day 8 · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg may leads to lower participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).
2 findings from 1 review
Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with gametocytes at day 3‐4, by PCR compared with no primaquine, with artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg leads to lower participants with gametocytes at day 8, by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
Presence of PIVKA II at day 25: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in presence of PIVKA II at day 25: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 25: 0.2 mg IV versus 0.2 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 25: 0.2 mg IV versus 0.2 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 25 ‐ 0.2 mg IV versus 0.5 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 25 ‐ 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Percent of days abstinent · people with co‐occurring depression and alcohol dependence
1 finding from 1 review
Amount of alcohol consumed, short term (3‐6 months) measured using the number of drinks/drinking day (in past week to 30 days) · people with co‐occurring depression and alcohol dependence
1 finding from 1 review
Intervention not reported
Subgroup analysis of infants operated on at less than 70 days of age who did not clear their jaundice by six months after Kasai portoenterostomy · infants with biliary atresia
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Number of standard drinks consumed per day over the last 30 days · concurrent problem alcohol and illicit drug users
1 finding from 1 review